Abstract
Californium-252 (252Cf), a fast-neutron emitting radioisotope, was used for neutron brachytherapy (NT) of 82 patients with advanced (stage III and IV) cervical cancer. The results were compared with caesium-137 brachytherapy; both isotopes were given in combination with high-dose fractionated pelvic radiotherapy. In patients with stage IIIB disease (ie, tumour to the pelvic side-wall), 252Cf intracavitary therapy resulted in 54% 5-year survival compared with 12% in the caesium group. To be effective, Cf-NT must be given before external beam (photon) therapy.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Actuarial Analysis
-
Adenocarcinoma / mortality
-
Adenocarcinoma / radiotherapy
-
Aged
-
Brachytherapy*
-
Californium / therapeutic use
-
Carcinoma, Small Cell / mortality
-
Carcinoma, Small Cell / radiotherapy
-
Carcinoma, Squamous Cell / mortality
-
Carcinoma, Squamous Cell / radiotherapy
-
Cesium Radioisotopes / therapeutic use
-
Fast Neutrons
-
Female
-
Follow-Up Studies
-
Humans
-
Middle Aged
-
Neoplasm Recurrence, Local
-
Radiation Injuries
-
Uterine Cervical Neoplasms / mortality
-
Uterine Cervical Neoplasms / radiotherapy*
Substances
-
Cesium Radioisotopes
-
Californium